Copyright Reports & Markets. All rights reserved.

Global Neuroendocrine Tumors (NETs) Treatment Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Neuroendocrine Tumors (NETs) Treatment Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Neuroendocrine Tumors (NETs) Treatment Consumption 2014-2024
        • 2.1.2 Neuroendocrine Tumors (NETs) Treatment Consumption CAGR by Region
      • 2.2 Neuroendocrine Tumors (NETs) Treatment Segment by Type
        • 2.2.1 Somatostatin Analogs (SSAs)
        • 2.2.2 Targeted Therapy
        • 2.2.3 Other
      • 2.3 Neuroendocrine Tumors (NETs) Treatment Consumption by Type
        • 2.3.1 Global Neuroendocrine Tumors (NETs) Treatment Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global Neuroendocrine Tumors (NETs) Treatment Sale Price by Type (2014-2019)
      • 2.4 Neuroendocrine Tumors (NETs) Treatment Segment by Application
        • 2.4.1 Hospitals
        • 2.4.2 Clinics
        • 2.4.3 Other
      • 2.5 Neuroendocrine Tumors (NETs) Treatment Consumption by Application
        • 2.5.1 Global Neuroendocrine Tumors (NETs) Treatment Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global Neuroendocrine Tumors (NETs) Treatment Value and Market Share by Application (2014-2019)
        • 2.5.3 Global Neuroendocrine Tumors (NETs) Treatment Sale Price by Application (2014-2019)

      3 Global Neuroendocrine Tumors (NETs) Treatment by Manufacturers

      • 3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Manufacturers
        • 3.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturers (2017-2019)
        • 3.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Manufacturers (2017-2019)
      • 3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Manufacturers
        • 3.2.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers (2017-2019)
        • 3.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Manufacturers (2017-2019)
      • 3.3 Global Neuroendocrine Tumors (NETs) Treatment Sale Price by Manufacturers
      • 3.4 Global Neuroendocrine Tumors (NETs) Treatment Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
        • 3.4.1 Global Neuroendocrine Tumors (NETs) Treatment Manufacturing Base Distribution and Sales Area by Manufacturers
        • 3.4.2 Players Neuroendocrine Tumors (NETs) Treatment Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Neuroendocrine Tumors (NETs) Treatment by Regions

      • 4.1 Neuroendocrine Tumors (NETs) Treatment by Regions
        • 4.1.1 Global Neuroendocrine Tumors (NETs) Treatment Consumption by Regions
        • 4.1.2 Global Neuroendocrine Tumors (NETs) Treatment Value by Regions
      • 4.2 Americas Neuroendocrine Tumors (NETs) Treatment Consumption Growth
      • 4.3 APAC Neuroendocrine Tumors (NETs) Treatment Consumption Growth
      • 4.4 Europe Neuroendocrine Tumors (NETs) Treatment Consumption Growth
      • 4.5 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Consumption Growth

      5 Americas

      • 5.1 Americas Neuroendocrine Tumors (NETs) Treatment Consumption by Countries
        • 5.1.1 Americas Neuroendocrine Tumors (NETs) Treatment Consumption by Countries (2014-2019)
        • 5.1.2 Americas Neuroendocrine Tumors (NETs) Treatment Value by Countries (2014-2019)
      • 5.2 Americas Neuroendocrine Tumors (NETs) Treatment Consumption by Type
      • 5.3 Americas Neuroendocrine Tumors (NETs) Treatment Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Neuroendocrine Tumors (NETs) Treatment Consumption by Countries
        • 6.1.1 APAC Neuroendocrine Tumors (NETs) Treatment Consumption by Countries (2014-2019)
        • 6.1.2 APAC Neuroendocrine Tumors (NETs) Treatment Value by Countries (2014-2019)
      • 6.2 APAC Neuroendocrine Tumors (NETs) Treatment Consumption by Type
      • 6.3 APAC Neuroendocrine Tumors (NETs) Treatment Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Neuroendocrine Tumors (NETs) Treatment by Countries
        • 7.1.1 Europe Neuroendocrine Tumors (NETs) Treatment Consumption by Countries (2014-2019)
        • 7.1.2 Europe Neuroendocrine Tumors (NETs) Treatment Value by Countries (2014-2019)
      • 7.2 Europe Neuroendocrine Tumors (NETs) Treatment Consumption by Type
      • 7.3 Europe Neuroendocrine Tumors (NETs) Treatment Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment by Countries
        • 8.1.1 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Value by Countries (2014-2019)
      • 8.2 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Consumption by Type
      • 8.3 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 Neuroendocrine Tumors (NETs) Treatment Distributors
      • 10.3 Neuroendocrine Tumors (NETs) Treatment Customer

      11 Global Neuroendocrine Tumors (NETs) Treatment Market Forecast

      • 11.1 Global Neuroendocrine Tumors (NETs) Treatment Consumption Forecast (2019-2024)
      • 11.2 Global Neuroendocrine Tumors (NETs) Treatment Forecast by Regions
        • 11.2.1 Global Neuroendocrine Tumors (NETs) Treatment Forecast by Regions (2019-2024)
        • 11.2.2 Global Neuroendocrine Tumors (NETs) Treatment Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Neuroendocrine Tumors (NETs) Treatment Forecast by Type
      • 11.8 Global Neuroendocrine Tumors (NETs) Treatment Forecast by Application

      12 Key Players Analysis

      • 12.1 Advanced Accelerator Applications
        • 12.1.1 Company Details
        • 12.1.2 Neuroendocrine Tumors (NETs) Treatment Product Offered
        • 12.1.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 Advanced Accelerator Applications News
      • 12.2 AVEO Oncology
        • 12.2.1 Company Details
        • 12.2.2 Neuroendocrine Tumors (NETs) Treatment Product Offered
        • 12.2.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 AVEO Oncology News
      • 12.3 Boehringer Ingelheim International
        • 12.3.1 Company Details
        • 12.3.2 Neuroendocrine Tumors (NETs) Treatment Product Offered
        • 12.3.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 Boehringer Ingelheim International News
      • 12.4 Hutchison MediPharma Limited
        • 12.4.1 Company Details
        • 12.4.2 Neuroendocrine Tumors (NETs) Treatment Product Offered
        • 12.4.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.4.4 Main Business Overview
        • 12.4.5 Hutchison MediPharma Limited News
      • 12.5 IpsenPharma
        • 12.5.1 Company Details
        • 12.5.2 Neuroendocrine Tumors (NETs) Treatment Product Offered
        • 12.5.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.5.4 Main Business Overview
        • 12.5.5 IpsenPharma News
      • 12.6 Novartis AG
        • 12.6.1 Company Details
        • 12.6.2 Neuroendocrine Tumors (NETs) Treatment Product Offered
        • 12.6.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.6.4 Main Business Overview
        • 12.6.5 Novartis AG News
      • 12.7 Pfizer, Inc
        • 12.7.1 Company Details
        • 12.7.2 Neuroendocrine Tumors (NETs) Treatment Product Offered
        • 12.7.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.7.4 Main Business Overview
        • 12.7.5 Pfizer, Inc News
      • 12.8 Progenics Pharmaceuticals
        • 12.8.1 Company Details
        • 12.8.2 Neuroendocrine Tumors (NETs) Treatment Product Offered
        • 12.8.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.8.4 Main Business Overview
        • 12.8.5 Progenics Pharmaceuticals News

      13 Research Findings and Conclusion

      Neuro Emotional Technique (NET) is a psycho-emotional therapy based on the physiological foundations of stress-related responses. As discovered in the late 1970’s, emotional responses are composed of neuropeptides (amino acid chains) and their receptors, which lie on neurons and other cells of remote tissues in the body. The neuropeptides are ejected from the neuron and carry the encoded “information” to other sites within the body. These neuropeptides are in a category of neurochemicals known as Information Substances (IS). ISs are released at times of stress-related arousal and become attached to remotely-positioned neuroreceptors.

      According to this study, over the next five years the Neuroendocrine Tumors (NETs) Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Neuroendocrine Tumors (NETs) Treatment business, shared in Chapter 3.

      This report presents a comprehensive overview, market shares, and growth opportunities of Neuroendocrine Tumors (NETs) Treatment market by product type, application, key manufacturers and key regions and countries.

      This study considers the Neuroendocrine Tumors (NETs) Treatment value and volume generated from the sales of the following segments:

      Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
      Somatostatin Analogs (SSAs)
      Targeted Therapy
      Other
      Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
      Hospitals
      Clinics
      Other

      This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
      Advanced Accelerator Applications
      AVEO Oncology
      Boehringer Ingelheim International
      Hutchison MediPharma Limited
      IpsenPharma
      Novartis AG
      Pfizer, Inc
      Progenics Pharmaceuticals

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Neuroendocrine Tumors (NETs) Treatment consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
      To understand the structure of Neuroendocrine Tumors (NETs) Treatment market by identifying its various subsegments.
      Focuses on the key global Neuroendocrine Tumors (NETs) Treatment manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Neuroendocrine Tumors (NETs) Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Neuroendocrine Tumors (NETs) Treatment submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      Buy now